Setting: 25 centers in the United States. Thyroid hormones are important modulators of metabolic activity in mammals and alter cholesterol and fatty acid levels through activation of the nuclear thyroid hormone receptor (THR). Our lead candidate, VK2809, is a novel, orally available small molecule thyroid hormone receptor agonist that possesses selectivity for liver tissue, as well as the beta receptor subtype, suggesting promise for the treatment of metabolic disorders, including non-alcoholic steatohepatitis (NASH). Selective agonists of the beta isoform of thyroid hormone receptor (TR) do not exhibit T3-induced cardiotoxicity and show a good safety profile in patients with NASH. In addition, the company is actively planning to initiate clinical studies for its thyroid hormone receptor beta agonist TERN-501 as monotherapy and in combination with its other pipeline assets . Harrison SA, Moussa S, Bashir M, et al. (B) Thyroid Hormone Receptors (TRs) act as transcriptional factors that regulate a . One compound was further profiled in a diet-induced mouse model of nonalcoholic steatohepatitis (NASH) and . Madrigal's most advanced clinical candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR) -selective agonist designed specifically to treat the underlying causes of NASH in the liver, while improving multiple atherogenic lipid profiles.. NASH, hypercholesterolemia and hyperlipidemia with low adverse effects. 4).The TRs are members of the nuclear hormone receptor (NR) superfamily that also includes receptors for steroid hormones, retinoids, and 1,25-dihydroxyvitamin D3 (5-7).These receptors are transcription factors that can . Hepatic thyroid hormone signaling has an important role in the development and progression of nonalcoholic steatohepatitis (NASH). Thyroid hormones (THs) elicit significant effects on numerous physiological processes, such as growth, development, and metabolism. The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. Our most advanced clinical candidate, resmetirom, is a once daily, oral thyroid hormone receptor (THR) -selective agonist that is currently being studied in Phase 3 trials. Resmetirom (MGL-3196) is a novel, highly selective thyroid beta-agonist, with a minimal side-effect profile, which avoids the alpha-side effects. Analysis of the relative distribution of the and subtypes of nuclear TH receptors (TR and TR) showed that TR and TR are responsible for cardiac and metabolic responses, respectively. TERN-501 is a thyroid hormone receptor beta (THR-) agonist with high metabolic stability, enhanced liver distribution and greater selectivity for THR- compared to other THR- agonists in . UniParc. thyroid hormone receptor beta A protein encoded by THRB on chromosome 3p24.2, which is a nuclear hormone receptor for triiodothyronine and one of several thyroid hormone receptors that mediate thyroid hormone's biological activity. The biotech's drug is one of the few NASH treatments that has advanced to late-stage testing, as the disease has proven difficult for drugmakers to crack. Two thyroid hormone receptor beta agonists - MGL-3196 and VK2809 - reduced liver fat and blood lipid levels in people with non-alcoholic fatty liver disease (NAFLD) and its more severe form, non-alcoholic steatohepatitis (NASH). Moreover, novel liver-specific ligands for thyroid hormone receptor beta 1 complete the spectrum of currently available NR-targeted drugs. A Seamless Phase 2a/2b, Double-Blind, Randomized, Multicenter, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41, a Thyroid Hormone Receptor Agonist, in Adults With Nonalcoholic Steatohepatitis (NASH) Estimated Study Start Date : March 30, 2022: Estimated Primary Completion Date : November 10, 2023 Once activated, these beta receptors play a role in reducing fibrosis and liver fat, lowering cholesterol levels, raising the heart rate, and improving metabolic health and function. Hepatic thyroid hormone signaling has an important role in the development and progression of nonalcoholic steatohepatitis (NASH). Nonalcoholic steatohepatitis (NASH) is characterized by liver inflammation and damage caused by a buildup of fat in the liver. Madrigal Pharmaceuticals is . The build-up of fat in the liver . 2 16 Abstract 17 Thyroid hormones are important modulators of metabolic activity in mammals and alter cholesterol 18 and fatty acid levels through activation of the nuclear thyroid hormone receptor (THR). Activation of thyroid hormone receptor (THR) has shown beneficial effects on metabolic alterations, including non-alcoholic fatty liver disease (NAFLD). Selected examples showed good in-vivo efficacy in a rat hypercholesterolemic model. The largest class of molecular targets for hormone-based NASH therapies is nuclear receptors [6,7]. SAN DIEGO, Nov. 19, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of a Phase 2b clinical trial of VK2809, its novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed non . VK2809 is an orally available small molecule agonist of the thyroid hormone receptor that possesses selectivity for liver tissue, as well as the beta receptor subtype, and has demonstrated promising therapeutic potential in a range of lipid disorders, including NASH. NAFLD NASH Hyperlipidemia Resmetirom Thyroid hormone receptor beta Hepatic Fibrosis: NASH resolution Thyroid hormone receptor agonist Cardiovascular Dyslipidemia Fatty liver disease Nonalcoholic steatohepatitis: Additional relevant MeSH terms: Layout table for MeSH terms; Agonism of THR- increases fatty acid metabolism via mitochondrial oxidation and affects cholesterol synthesis and metabolism. Patients were eligible for inclusion if they had LDL cholesterol 110 mg/dL, liver fat content 8% by MRI-PDFF, and triglycerides 120 mg/dL, with a body mass index of 18.5 to 40, free . Selective agonists of the beta isoform of thyroid hormone receptor (TR) do not exhibit T3-induced cardiotoxicity and show a good safety profile in patients with NASH. In some cases, NAFLD progresses to NASH, which frequently advances into fibrosis and cirrhosis, and 4-27% NASH cases develop HCC . A lack of thyroid hormones is not compatible with normal health. Function. Therefore, analogues with TR . This Thyroid Hormone Receptor Beta (TR) assay kit is an all-inclusive firefly luciferase reporter assay system that includes, in addition to TR Reporter Cells, two optimized media for use during cell culture and (optionally) in diluting the test samples, a reference agonist, Luciferase Detection Reagent, a cell culture-ready assay plate, and a detailed protocol. 2000;141(9):3057-64. . Thyroid Receptor beta Coactivator Assay (Invitrogen, PV4686) with slight, optimized modifi-cations. . However, there are no studies on the prevalence of NAFLD in hyperthyroid patients, and little is known about the association of . Thyroid hormone (TH) is potent to influence multiple aspects of lipid, carbohydrate, protein and mineral metabolism [].Through binding to nuclear TH receptors (TR), TH can modulate the expression of target genes [].Physiological inverse relationship between TH, such as thyroxine (T4) and triiodothyronine (T3), and thyroid-stimulating hormone (TSH) are maintained through a classic negative . NASH, which presents with liver . Thyroid hormone analogues and thyroid receptor beta antagonist have been used to reduce liver fat content in animal models. Although no drugs have been approved for the treatment of NASH, thyroid hormone receptor (THR- agonists have demonstrated potential to reduce liver fat, restore liver functions, and possibly reverse fibrosis [1-4 . INTRODUCTION. Endocrinology. Mutations in the gene encoding thyroid hormone receptor (TR) have been described in the majority of families with RTH. 190160. The companies and academics are working to assess challenges and seek opportunities that could influence Thyroid Hormone Receptor Agonists R&D. The therapies . Use of the oxadiazolone acid isostere in triiodothyronine analogs yielded potent and selective agonists for the thyroid hormone receptor . The company said the therapeutic helped . The effects of exogenous thyroid hormones (thyroxine and triiodothyronine) on beta-adrenergic receptors in the rat myocardium were investigated. Gloss B, Wang-Iverson DB, Zhang H, Volodarsky T, et al. While the systemic levels of thyroid hormone might remain stable, there is evidence that the intracellular signaling machinery consisting of transporters, deiodinases and receptors could be altered in NASH. The development of thyroid hormone (TH) analogues was prompted by the attempt to exploit the effects of TH on lipid metabolism, avoiding cardiac thyrotoxicosis. The thyroid hormone receptor-beta-selective agonist GC-1 differentially affects plasma lipids and cardiac activity. The NASH drug that is the most advanced in terms of clinical trial research is the farnesoid X receptor (FXR) agonist obeticholic acid (Ocaliva, Intercept Pharmaceuticals). THR- (Thyroid Hormone Receptor Beta) Agonists Several THR- agonists are currently in the clinic and have demonstrated favorable effects on plasma lipid levels, liver fat burden, as well as liver histology in NASH patients. Our lead THR- agonist, The protein encoded by this gene is a nuclear hormone receptor for triiodothyronine.It is one of the several receptors for thyroid hormone, and has been shown to mediate the biological activities of thyroid hormone. General model for thyroid hormone (T3) generation and action in the nucleus. Non-alcoholic fatty liver disease (NAFLD) and NASH, its more severe form, are . RefSeq. Now Read: Terns Pharmaceuticals GAAP EPS of -$0.55 Comments Help pages, FAQs, UniProtKB manual, documents, news archive and Biocuration projects. Abstract. While the systemic levels of thyroid hormone might remain stable, there is evidence that the intracellular signaling machinery consisting of transporters, deiodinases and receptors could be altered in NASH. Deiodinase 3 (D3) converts T4 to the inactive rT3. Cardiac membranes from hyperthyroid rats . Briefly, the assay was performed in 384-well, black microplate plates . There are currently several small molecule drug candidates at various . Knockout studies in mice suggest that the different receptors, while having certain extent of redundancy, may mediate different functions of thyroid hormone. Currently, there are 19 several THR agonists in clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) that have 20 demonstrated the potential to reduce liver fat and . Synopsis: Of 125 adults with NASH fibrosis 1-3 and greater than 10% hepatic fat, 84 . Thyroid hormones (THs) elicit significant effects on numerous physiological processes, such as growth, development, and metabolism. Terns plans to begin a trial of TERN-101 and TERN-501, a thyroid hormone receptor beta agonist ("THR-"), in 1H 2022. High affinity receptor for thyroid hormones, including triiodothyronine and thyroxine. Pharmacological control of these pathways would likely impact the treatment of several human diseases characterized by altered metabolism, growth or . Resmetirom, a thyroid hormone receptor agonist, appeared to reduce liver fat and fibrosis, as determined by biomarkers and non-invasive imaging, in people with non-alcoholic steatohepatitis (NASH), according to a presentation at the 2021 International Liver Congress. TERN-501 was generally safe and . In 2019, the company initiated the Phase 2b VOYAGE trial. NAFLD NASH Hyperlipidemia Resmetirom Thyroid hormone receptor beta Hepatic Fibrosis: NASH resolution Thyroid hormone receptor agonist Cardiovascular Dyslipidemia Fatty liver disease Nonalcoholic steatohepatitis: Additional relevant MeSH terms: Layout table for MeSH terms; Transforming the Treatment of NASH. MGL-3196, a selective thyroid hormone receptor-beta agonist significantly decreases hepatic fat in NASH patients at 12 weeks, the . Sequence archive. Although no drugs have been approved for the treatment of NASH, thyroid hormone receptor. The compound can be effective in lowering cholesterol with minimum or no adverse effects on the heart or thyroid hormone axis. A lack of thyroid hormones is not compatible with normal health. UniProtKB. THR is the main receptor for thyroid hormones in the liver and plays an essential role in lipid metabolism. and beta-thyroid hormone receptor mRNAs, including the beta 2-subtype, Hepatic thyroid hormone signaling has an important role in the development and progression of nonalcoholic steatohepatitis (NASH). (A) Thyroxine (T4), the prevalent form of thyroid hormone (TH) produced by the thyroid gland, once released is converted to T3, the major form of TH, by deiodinases 1 and 2 (D1 and D2). (B) Thyroid Hormone Receptors (TRs) act as transcriptional factors that regulate a . . Currently, there are several THR agonists in clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) that have demonstrated the potential to reduce liver fat and restore liver function. Resmetirom (MGL-3196) is a liver-directed, orally active, selective thyroid hormone receptor- agonist designed to improve NASH by increasing hepatic fat metabolism and reducing lipotoxicity. x; UniProtKB. Pennsylvania-based Madrigal said data from the Phase III MAESTRO-NAFLD-1 safety study of resmetirom showed that the thyroid hormone receptor-beta agonist was safe and well-tolerated at daily dosing levels of 80 mg and 100 mg. Not only is resmetirom showing itself to be safe, but it is also effective. This trial is a . Terns Pharmaceuticals announced positive top-line results from a phase 1 clinical trial of TERN-501, a thyroid hormone receptor beta agonist for the treatment of nonalcoholic steatohepatitis . TERN-501 is a thyroid hormone receptor beta (THR-) agonist with high metabolic stability, enhanced liver distribution and greater selectivity for THR- compared to other THR- agonists in development. . To identify clinical trials of the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, we searched PubMed for English language articles published from Jan 1, 2007, to July 1, 2019, with the search terms "NAFLD", "NASH", "fatty liver", "thyroid hormone", and "thyroid hormone receptor beta". Viking's VK2809 - a thyroid hormone receptor beta agonist - was able to cut fat in the liver by 57%-60% on average compared to a 9% drop for placebo after 12 weeks' treatment, tackling one of the main biomarkers for NASH and other forms of non-alcoholic fatty liver disease (NAFLD), and also reduced LDL cholesterol. (A) Thyroxine (T4), the prevalent form of thyroid hormone (TH) produced by the thyroid gland, once released is converted to T3, the major form of TH, by deiodinases 1 and 2 (D1 and D2). Phase 3 Development of Resmetirom: a Liver-Directed Thyroid Hormone Receptor (THR)-Beta Agonist for the Treatment of Patients with NASH and Significant Liver FibrosisImpacting NASH: Focus on Liver and Cardiovascular Benefits(as presented at EASL 2021) The contribution of metabolic co-morbidities and hepatic thyroid hormone dysregulation to the . Thyroid hormones have some potentially therapeutic actions by binding to specific nuclear receptors [thyroid hormone receptors (TR)] of which the TR isoform is liver specific and a putative target for the treatment of dyslipidemia and fatty liver. 1).In the TR gene, 43 mutations in 86 families have been found in cluster 1 (corresponding to amino acids 429-460), 49 mutations in 113 families have . Clinical studies also demonstrated that thyroid hormone analogues may improve NAFLD [13, 14]. The activity of the thyroid hormones, L-thyroxin (T4) and L-triiodothyronine (T3), is mediated by thyroid hormone nuclear receptors (TRs) (for a recent review see ref. Most THs effects are mediated by two different thyroid hormone receptor (TR) isoforms, namely TR and TR, with the TR isoform known to be responsible for the main beneficial effects of TH on . (THR-) agonists have demonstrated potential to reduce liver fat, restore liver functions, and possibly reverse . Deiodinase 3 (D3) converts T4 to the inactive rT3. Protein knowledgebase. P10828. Resmetirom is designed to target the underlying causes of NASH by reducing or eliminating liver fat (steatosis) as well as reducing liver inflammation, liver cell . Positive topline Phase 3 data from the MAESTRO-NAFLD-1 safety study demonstrate resmetirom was . The Phase 3 MAESTRO-NASH trial is expected to enroll 900 patients with biopsy-proven NASH (fibrosis stage 2 or 3), randomized 1:1:1 to receive resmetirom 80 mg once a day, 100 mg once a day, or . While the systemic levels of thyroid hormone might remain stable, there is evidence that the intracellular signaling machinery consisting of transporters, deiodinases and receptors could be altered in NASH. Thyroid hormones increase energy expenditure and have catabolic properties, acting via the thyroid hormone receptor (THR), a nuclear receptor with different isoforms. The potent beta-adrenergic antagonist, (-)-[3H]dihydroalprenolol, was used to directly estimate the number and affinity of beta-adrenergic receptors in rat heart membranes from control and hyperthyroid rats. Specifically, Madrigal's drug is designed to act on a protein called thyroid hormone receptor-beta while avoiding the related thyroid hormone receptor-alpha, which regulates how the . Glucagon and glucagon-like peptide-1 (GLP-1) agonists, which mimic hormones that regulate appetite and affect glucose and lipid metabolism. Treatments under study for NAFLD and NASH include: Farnesoid X receptor (FXR) agonists, which regulate bile acid synthesis and play a role in lipid and glucose metabolism. DOI: 10.3389/fmed.2020.00331 Corpus ID: 220408721; Selective Thyroid Hormone Receptor-Beta (TR) Agonists: New Perspectives for the Treatment of Metabolic and Neurodegenerative Disorders Here, we investigated the effect of TG68, a novel THR agonist, on fatty liver accumulation and liver injury in mice fed a high-fat diet (HFD). Amongst the most important functions of thyroid hormone receptors are regulation of metabolism and heart rate. Study design: Randomized, double-blind, placebo-controlled study. The liver-targeting properties of our TR . In addition, they play critical roles in the development of organisms. VK2809 works by activating thyroid beta receptors. Thyroid hormone receptor beta. Most THs effects are mediated by two different thyroid hormone receptor (TR) isoforms, namely TR and T NAFLD and NASH are often associated with obesity and the metabolic syndrome. Report Highlights. The aim of this study was to investigate whether two novel TR agonists, the prodrug TG68 and the active compound IS25 could stimulate hepatocyte proliferation without T3/TR . In patients with non-alcoholic steatohepatitis (NASH), treatment with THR- agonists decreased hepatic steatosis and circulating lipids, and induced resolution of NASH. Considering the results of this trial, it seems as though the drug is capable of reaching these goals. . NM_000461. We initiated a Phase 2a clinical trial in NASH patients including both monotherapy and combination arms of TERN-501 and TERN-101 and . . injury, and progressive liver fibrosis. Report Highlights. Keywords: selective thyromimetics, prodrugs, thyroid hormone receptors, dyslipidemia, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), myelin, clinical trials . General model for thyroid hormone (T3) generation and action in the nucleus. An intrahepatic hypothyroidism has been shown to be present in NASH and potentially contributes to its pathophysiology [ 70 ]. Activation of hepatic thyroid hormone receptor (THR-) is associated with systemic lipid lowering, increased bile acid synthesis, and fat oxidation. Help. However, clinical material from human liver biopsies of . All mutations affect the LBD or adjacent hinge region of the TR molecule and are distributed in three clusters (Fig. Selective agonists of the beta isoform of thyroid hormone receptor (TR) do not exhibit T3-induced cardiotoxicity and show a good safety profile in patients with NASH. The signaling pathways activated by thyroid hormone receptors (THR) are of fundamental importance for organogenesis, growth and differentiation, and significantly influence energy metabolism, lipid utilization and glucose homeostasis. 16 Phase 2 clinical data showed that Resmetirom treatment resulted in a significant reduction in hepatic fat in patients with NASH, 17 and supported its advancement into Phase 3 clinical development . C57BL/6 mice fed HFD for 17 or 18 weeks, a time when all mice developed massive . 2.2.7 Resmetirom (MGL-3196) Thyroid hormones play a central role in controlling lipid metabolism through the activation of the receptor, influencing the levels of serum cholesterol and triglycerides . Background Non-alcoholic steatohepatitis (NASH) is characterised by hepatic steatosis, inflammation, hepatocellular . steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), myelin, clinical trials. Apart from FXR ligands, BA signalling can be targeted by mimetics of FXR-activated fibroblast growth factor 19, modulation of their enterohepatic circulation through uptake inhibitors in hepatocytes and . Core tip: Fatty liver is associated with increased risk for the development of cirrhosis and hepatocellular carcinoma. UniProt. Alternative name(s): Nuclear receptor subfamily 1 group A . Aligos' poster presentation, titled "Preclinical development of ALG-055009 as a Potent and Selective Thyroid Hormone Receptor Beta Agonist for the Treatment of NASH", highlighted key preclinical data for the company's lead NASH candidate ALG-055009, a thyroid hormone receptor- (THR-) agonist. Background: Nonalcoholic steatohepatitis (NASH) is characterized by liver inflammation and damage caused by a buildup of fat in the liver. "VK2735 is the third compound to enter active clinical development at Viking, joining our most advanced program VK2809, a novel thyroid receptor beta agonist in a Phase 2b study in NASH, and . Currently, there are several THR agonists in clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) that have demonstrated the potential to reduce liver fat and restore liver function. The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which . The thyroid hormone receptor is a type of nuclear receptor that is activated by binding thyroid hormone. Terns Pharmaceuticals Inc (NASDAQ: TERN) reported top-line results from a Phase 1 trial of TERN-501, a thyroid hormone receptor beta (THR-) agonist, for NASH. Abstract: Thyroid hormones are important modulators of metabolic activity in mammals and alter cholesterol and fatty acid levels through activation of the nuclear thyroid hormone receptor (THR). For the moment, these are emerging technologies which have not been approved by regulatory agencies to assess the benefit of therapies in NASH. In . TERN-501 is a thyroid hormone receptor beta (THR-) agonist with high metabolic stability, enhanced liver distribution and greater selectivity for THR- compared to other THR- agonists in . . TERN-501 is a Thyroid Hormone Receptor beta (THR-) agonist with high metabolic stability, enhanced liver distribution and greater selectivity for THR- compared to other THR- agonists in development. Thyroid hormone receptor beta (THR-) is a nuclear hormone receptor that is highly expressed in the liver and plays a central role in lipid metabolism, regulation of blood cholesterol and . The companies and academics are working to assess challenges and seek opportunities that could influence Thyroid Hormone Receptor Agonists R&D. The therapies . A thyroid hormone receptor agonist and its use in the treatment of a disease associated thyroid hormone receptor beta are described.